Health Care·Pharmaceuticals·$6.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.03 | N/A | -251.54% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.03 | N/A | -251.54% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns over current performance and did not offer future guidance. They emphasized the need for strategic adjustments.
Management did not provide specific guidance for future quarters.
The company acknowledged challenges in meeting earnings expectations.
Terns Pharmaceutical's earnings report indicates significant challenges, particularly with a larger-than-expected loss per share. The stock's slight decline of 0.08% reflects investor concerns about the company's future performance and lack of guidance. Without clear direction, investors may remain cautious as they assess the company's next steps.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
USA RARE EARTH INC Class A
Mar 30, 2026